Tag: Lucentis Biosimilar
Lupin Gets U.S. FDA Approval for Ranluspec™ to Treat Retinal Disorders
Lupin Limited has secured U.S. FDA approval for Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Genentech’s Lucentis® — a milestone that reshapes patient access to sight-saving biologics across...